Kunpeng Bio has actively participated in the auction of state-owned industrial land. As of September 19, 2019, it had successfully auctioned Kundi.com's "2019" Gongzai No. 35, the east side of Gucheng Road in the high-tech zone, and the second side of Chenfeng Road. The land area is 33,339 square meters (50 acres), which is industrial land.
The successful land auction provided a solid guarantee for the company's subsequent project development and construction, and laid a good foundation for the company to complete its development goals.
In this hot land, our company will strive to become a new benchmark and new highlight for companies in the biomedical field.
Suzhou Kunpeng Biotechnology Co., Ltd. was established in February 2013 and is located in Kunshan Bio-Pharmaceutical Industrial Park, Jiangsu. The company has a registered capital of 84 million yuan and more than 70 employees. The company takes "providing drugs, technologies and services for human disease control" as its mission and is committed to the research, development, production and sales of high-end protein drugs. In the field of diabetes treatment drugs, the company used its unique "protein-targeted modification technology" platform to complete: "recombinant human insulin, insulin glargine, insulin aspart, insulin deguer, liraglutide, and somaglutide" The technology development of multiple diabetes drugs will gradually achieve mass production in the future.
The company has established a complete R & D and pilot test platform, and has established a professional team including several technical experts at home and abroad. Invested 600 million yuan, and is a high-end biomedical industrialization base built in accordance with the GMP standards of NMPA, the US FDA, and the European Union EMA. It is expected to produce more than 50 million drugs per year and achieve an output value of 5 billion yuan. In the next 5 years, the company will rely on an efficient R & D system, advanced production technology and international quality management. It will obtain clinical approvals for 3 varieties per year, and 2 products will be produced at a faster rate. It will continue to develop advanced technology, excellent quality, and meet domestic requirements. As well as the drugs required for global disease treatment, it has become a leading domestic biopharmaceutical company.